Seeing double: the low-carb diet

No abstract available

The Paths Social-Emotional Education Curriculum with Reflections on Felt Bodily Experience and Buddhist Principles

This report focuses on the PATHS (Promoting Alternative Thinking Strategies) social-emotional education curriculua for preschool and elementary school students developed in the 1990s, by Dr. Mark Greenberg and colleagues at Pennsylvania State University, University Park, Pennsylvania, USA. In considering Greenberg’sdiscussion of the PATHS program with His Holiness the Dalai Lama, the article first offers a brief Buddhist context for emotioneducation. Of interest is that the PATHS curriculum also uses the concept of “feelings that arise in the body” and so in the later part of the article I draw out the implications of this concept in my discussion on the nature of bodily experienced emotions. In thisdiscussion, I also give reference to developments in Humanistic Psychology, Neuropsychology and Buddhist mindfulnessmeditation

Consolidated health economic evaluation reporting standards (CHEERS) statement

<p>Economic evaluations of health interventions pose a particular challenge for reporting. There is also a need to consolidate and update existing guidelines and promote their use in a user friendly manner. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement is an attempt to consolidate and update previous health economic evaluation guidelines efforts into one current, useful reporting guidance. The primary audiences for the CHEERS statement are researchers reporting economic evaluations and the editors and peer reviewers assessing them for publication.</p> <p>The need for new reporting guidance was identified by a survey of medical editors. A list of possible items based on a systematic review was created. A two round, modified Delphi panel consisting of representatives from academia, clinical practice, industry, government, and the editorial community was conducted. Out of 44 candidate items, 24 items and accompanying recommendations were developed. The recommendations are contained in a user friendly, 24 item checklist. A copy of the statement, accompanying checklist, and this report can be found on the ISPOR Health Economic Evaluations Publication Guidelines Task Force website (www.ispor.org/TaskForces/EconomicPubGuidelines.asp).</p> <p>We hope CHEERS will lead to better reporting, and ultimately, better health decisions. To facilitate dissemination and uptake, the CHEERS statement is being co-published across 10 health economics and medical journals. We encourage other journals and groups, to endorse CHEERS. The author team plans to review the checklist for an update in five years.</p&gt

Bees of Maine, with a State Species Checklist

We present a new county checklist developed from bee research in Maine since the 1800s. The list contains 278 bee species in 37 genera and 6 families, of which all but 8 are native, with ≥50 taxa each in Andrena and Lasioglossum. Data for 16 counties from publications, museum collections, and recent surveys varied in number of species from 8 (Androscoggin) to 197 (Hancock). Research since 1930 on Vaccinium angustifolium (Lowbush Blueberry) led to many records. Twenty-one species are considered unusual, including 3 first recorded in 2016: Epeoloides pilosulus, Melitta melittoides, and Holcopasites calliopsidis. Maine records provide evidence of declines in Bombus affinis, decline in B. terricola followed by partial recovery, and increase in B. impatiens. Crops that should be studied regarding associated bees are Malus pumila (Apple), Vaccinium corymbosum (Highbush Blueberry), Vaccinium macrocarpon (American Cranberry), and Curcurbitaceae (cucurbits). Montane, sandy, and island habitats were identified as priorities for future sampling. We discuss records of bee species from New England relevant to understanding the Maine fauna, bee diversity, changes in abundance, cleptoparasitism, pesticide impacts, habitat requirements, and climate change

International Lessons in New Methods for Grading and Integrating Cost Effectiveness Evidence into Clinical Practice Guidelines

Economic evidence is influential in health technology assessment world-wide. Clinical Practice Guidelines (CPG) can enable economists to include economic information on health care provision. Application of economic evidence in CPGs, and its integration into clinical practice and national decision making is hampered by objections from professions, paucity of economic evidence or lack of policy commitment. The use of state-of-art economic methodologies will improve this. Economic evidence can be graded by 'checklists' to establish the best evidence for decision making given methodological rigor. New economic evaluation checklists, Multi-Criteria Decision Analyses (MCDA) and other decision criteria enable health economists to impact on decision making world-wide. We analyse the methodologies for integrating economic evidence into CPG agencies globally, including the Agency of Health Research and Quality (AHRQ) in the USA, National Health and Medical Research Council (NHMRC) and Australian political reforms. The Guidelines and Economists Network International (GENI) Board members from Australia, UK, Canada and Denmark presented the findings at the conference of the International Health Economists Association (IHEA) and we report conclusions and developments since. The Consolidated Guidelines for the Reporting of Economic Evaluations (CHEERS) 24 item check list can be used by AHRQ, NHMRC, other CPG and health organisations, in conjunction with the Drummond ten-point check list and a questionnaire that scores that checklist for grading studies, when assessing economic evidence. Cost-effectiveness Analysis (CEA) thresholds, opportunity cost and willingness-to-pay (WTP) are crucial issues for decision rules in CEA generally, including end-of-life therapies. Limitations of inter-rater reliability in checklists can be addressed by including more than one assessor to reach a consensus, especially when impacting on treatment decisions. We identify priority areas to generate economic evidence for CPGs by NHMRC, AHRQ, and other agencies. The evidence may cover demand for care issues such as involved time, logistics, innovation price, price sensitivity, substitutes and complements, WTP, absenteeism and presentism. Supply issues may include economies of scale, efficiency changes, and return on investment. Involved equity and efficiency measures may include cost-of-illness, disease burden, quality-of-life, budget impact, cost-effective ratios, net benefits and disparities in access and outcomes.. Priority setting remains essential and trade-off decisions between policy criteria can be based on MCDA, both in evidence based clinical medicine and in health planning

Solution to the Ward Identities for Superamplitudes

Supersymmetry and R-symmetry Ward identities relate on-shell amplitudes in a supersymmetric field theory. We solve these Ward identities for (Next-to)^K MHV amplitudes of the maximally supersymmetric N=4 and N=8 theories. The resulting superamplitude is written in a new, manifestly supersymmetric and R-invariant form: it is expressed as a sum of very simple SUSY and SU(N)_R-invariant Grassmann polynomials, each multiplied by a "basis amplitude". For (Next-to)^K MHV n-point superamplitudes the number of basis amplitudes is equal to the dimension of the irreducible representation of SU(n-4) corresponding to the rectangular Young diagram with N columns and K rows. The linearly independent amplitudes in this algebraic basis may still be functionally related by permutation of momenta. We show how cyclic and reflection symmetries can be used to obtain a smaller functional basis of color-ordered single-trace amplitudes in N=4 gauge theory. We also analyze the more significant reduction that occurs in N=8 supergravity because gravity amplitudes are not ordered. All results are valid at both tree and loop level.Comment: 29 pages, published versio

Economics methods in Cochrane systematic reviews of health promotion and public health related interventions.

Peer reviewedPublisher PD

Zero temperature string breaking in lattice quantum chromodynamics

The separation of a heavy quark and antiquark pair leads to the formation of a tube of flux, or "string", which should break in the presence of light quark-antiquark pairs. This expected zero-temperature phenomenon has proven elusive in simulations of lattice QCD. We study mixing between the string state and the two-meson decay channel in QCD with two flavors of dynamical sea quarks. We confirm that mixing is weak and find that it decreases at level crossing. While our study does not show direct effects of internal quark loops, our results, combined with unitarity, give clear confirmation of string breaking.Comment: 20 pages, 7 figures. With small clarifications and two additions to references. Submitted to Phys. Rev.

Meteor Trail Advection Observed During the 1998 Leonid Shower

Sodium resonance lidar observations of meteor trails are reported from the 1998 Leonid shower experimental at the Starfire Optical Range Kirtland Air Force Base, NM (35.0º N, 106.5º W ). The lidar was operating in a spatially scanning mode that allowed tracking for up to one half-hour. Three trails are presented here whose motion allowed inference of radial as well as vector wind components and apparent diffusivities. The winds are derived independently using the narrow linewidth sodium (Na) resonance Doppler lidar technique and are compared with the tracking results

An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations?:Analysis and recommendations

Introduction: The new European Union (EU) Regulations for medical devices (MDs) and health technology assessment (HTA) are welcome developments that will hopefully increase the quality of clinical evidence for MDs and reduce fragmentation in the EU market access process. To fully exploit anticipated benefits, their respective assessment processes should be closely coordinated, particularly for promising, highly innovative MDs. Accelerated approval is worth exploring for certain categories of high-risk MDs to keep the EU regulatory process competitive compared to ad-hoc accelerated MD approval processes elsewhere (e.g., US). Areas covered: Problems observed in worldwide accelerated drug and MD regulatory approval programs are reviewed, including greater uncertainty in pre-market clinical evidence generation and lack of oversight for post-approval evidence requirements. Implications for MD approval, HTA and coverage are explored. Expert opinion: Through analysis of two decades of drug and MD accelerated approval programs worldwide, recommendations for an Accelerated Access Pathway for select innovative, high-risk MDs are proposed that can fit the EU context, leverage the two new regulations, increase opportunities for Expert Panels to provide timely advice regarding manufacturers’ evidence generation plans along the MD lifecycle (pre-, post-market), and safely speed patient access while promoting increased collaboration among Member States on coverage decisions.</p